Asset Management One Co. Ltd. Acquires 12,148 Shares of Royalty Pharma PLC (NASDAQ:RPRX)

Asset Management One Co. Ltd. increased its holdings in Royalty Pharma PLC (NASDAQ:RPRX) by 8.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 164,931 shares of the biopharmaceutical company’s stock after acquiring an additional 12,148 shares during the quarter. Asset Management One Co. Ltd.’s holdings in Royalty Pharma were worth $5,134,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Kentucky Retirement Systems Insurance Trust Fund bought a new position in Royalty Pharma in the 1st quarter worth $349,000. Kentucky Retirement Systems bought a new position in Royalty Pharma in the first quarter worth about $819,000. Advisor Resource Council bought a new position in Royalty Pharma in the first quarter worth about $2,595,000. Good Steward Wealth Advisors LLC purchased a new stake in Royalty Pharma in the first quarter worth about $205,000. Finally, Autumn Glory Partners LLC bought a new stake in Royalty Pharma during the 1st quarter valued at approximately $218,000. Institutional investors own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on RPRX. Citigroup reissued a “buy” rating on shares of Royalty Pharma in a research report on Friday, March 28th. Morgan Stanley started coverage on Royalty Pharma in a research note on Friday, May 16th. They issued an “overweight” rating and a $51.00 price target on the stock. Finally, Wall Street Zen downgraded Royalty Pharma from a “buy” rating to a “hold” rating in a report on Sunday. One research analyst has rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $47.33.

Royalty Pharma Price Performance

Shares of NASDAQ RPRX opened at $35.87 on Friday. The company has a 50 day moving average of $33.47 and a 200 day moving average of $31.59. The company has a quick ratio of 1.56, a current ratio of 1.56 and a debt-to-equity ratio of 0.68. Royalty Pharma PLC has a twelve month low of $24.05 and a twelve month high of $36.32. The firm has a market cap of $20.17 billion, a P/E ratio of 19.39, a PEG ratio of 1.84 and a beta of 0.48.

Royalty Pharma (NASDAQ:RPRX) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.99 by $0.07. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. The business had revenue of $839.00 million for the quarter, compared to analysts’ expectations of $724.69 million. As a group, research analysts expect that Royalty Pharma PLC will post 4.49 EPS for the current fiscal year.

Royalty Pharma Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th were given a $0.22 dividend. The ex-dividend date was Friday, May 16th. This represents a $0.88 annualized dividend and a yield of 2.45%. Royalty Pharma’s payout ratio is 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.